封面
市场调查报告书
商品编码
1606423

新抗原癌症疫苗市场,按产品、按类型、按给药途径、按传递机制、按应用、按国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Neoantigen Cancer Vaccine Market, By Product, By Type, By Route of Administration, By Delivery Mechanism, By Application, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日期: | 出版商: AnalystView Market Insights | 英文 317 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年新抗原癌症疫苗市场规模为460.5943亿美元,2024年至2032年复合年增长率为73.40%。

新抗原癌症疫苗市场-市场动态

旨在定制患者治疗的个人化医疗的日益普及预计将推动市场扩张。这种方法强调制定专门针对个别患者特征(例如遗传特征、肿瘤特征和整体健康状况)的治疗计划。该方法的核心是新抗原疫苗,它是根据患者肿瘤中发现的独特突变精心製作的。值得注意的是,市场上的个人化药物数量从 132 种增加到 286 种,这些疗法占 FDA 2019 年批准的新药的 25%。

此外,公共和私营部门的资金增加,包括製药公司和创投家的捐款,正在推动这一领域的研究和开发工作。然而,製造流程的复杂性可能会对市场成长构成挑战。

新抗原癌症疫苗市场 - 关键见解

根据我们的研究分析师分享的分析,预计全球市场在预测期内(2024-2032)每年将以 73.40% 左右的复合年增长率成长

根据产品细分,个人化预计将在 2023 年显示最大的市场份额

按类型划分,2023年核酸为主导类型

根据应用细分,2023年肺癌为主导类型

按地区划分,北美是 2023 年的主要收入来源

新抗原癌症疫苗市场-細項分析:

全球新抗原癌症疫苗市场根据产品、类型、给药途径、输送机制、应用和地区进行细分。

市场根据产品分为两个部分:个人化和现成的。个性化细分市场在市场上占据主导地位。个人化新抗原疫苗通常与检查点抑制剂(例如 PD-1 或​​ CTLA-4 抑制剂)合併使用,以增强免疫反应。这种组合策略正在研究中,以解决现有免疫疗法的缺点并提高患者的治疗效果。

市场依类型分为四大类:树突状细胞、核酸、合成长肽、肿瘤细胞。核酸品类在市场上处于领先地位。新抗原癌症疫苗市场与核酸技术的进步密切相关,特别是在开发旨在解决肿瘤特异性突变的新型疫苗方面。

根据给药途径,市场分为三类:肌肉注射、静脉注射和透皮注射。新抗原癌症疫苗市场正在经历显着成长,不同的给药途径对于这些客製化疗法的进步和推广至关重要。

根据传递机制,市场分为四个部分:脂质体、病毒体、基因枪、电穿孔和其他。这些机制对于有效地将个人化疫苗递送至目标细胞至关重要,从而促进对癌症特异性新抗原的强大免疫反应。

根据应用,市场分为四类:脑癌、胃肠癌、肺癌、黑色素瘤和其他。肺癌在市场上处于领先地位。就肺癌而言,突变负担的增加提供了多种潜在的新抗原作为靶向,使个人化疫苗成为一种非常有前途的方法。

新抗原癌症疫苗市场-地理洞察

北美拥有健全的临床试验框架,有许多研究机构和医院从事新抗原疫苗的开发。该地区的监管环境有利于简化试验流程,促进创新疗法的进步和评估。癌症几乎影响了美国的每个人,公众对增加癌症研究资金也给予了大力支持。 ASCO 最近进行的一项涉及 4,000 多名美国人的调查显示,大约 73% 的人认为政府应该分配更多资源来发现癌症的治疗方法,即使这需要提高税收或增加国家赤字。在基因组技术进步的推动下,欧洲是第二大市场扩张地区。总体而言,新抗原癌症疫苗的全球环境充满活力,在不同地区提供了大量的成长机会。

新抗原癌症疫苗市场-竞争格局:

新抗原癌症疫苗市场呈现出高度竞争的环境,主要参与者积极利用尖端技术、建立策略联盟并在研发方面进行大量投资。这些公司正与研究机构、医疗机构和其他生技公司合作,加强研发力度,加速新抗原疫苗的研发。在持续的技术进步和提高患者治疗效果的承诺的推动下,竞争格局预计将迅速发生变化。

最新进展:

2024 年 9 月 10 日,OSE Immunotherapeutics SA 宣布开始针对 Tedopi 进行名为「Artemia」的国际 3 期临床试验,Tedopi 是一种基于新表位的治疗性癌症疫苗,旨在用于现成应用。该试验旨在为诊断为转移性非小细胞肺癌(NSCLC)的患者提供二线治疗。该研究已获得美国 FDA、加拿大、欧洲和英国等 14 个国家卫生当局的审查和批准,标誌着 Tedopi 的註册流程以及 HLA 伴随诊断的开发取得了重大进展-A2阳性患者。

目录

第 1 章:新抗原癌症疫苗市场概述

  • 研究范围
  • 市场预估年份

第 2 章:执行摘要

  • 市场片段
    • 新抗原癌症疫苗市场片段(按产品)
    • 新抗原癌症疫苗市场片段(按类型)
    • 按给药途径分類的新抗原癌症疫苗市场片段
    • 新抗原癌症疫苗市场片段(依传递机制)
    • 新抗原癌症疫苗市场片段(按应用)
    • 新抗原癌症疫苗市场片段(按国家/地区)
    • 按地区分類的新抗原癌症疫苗市场片段
  • 竞争洞察

第 3 章:新抗原癌症疫苗主要市场趋势

  • 新抗原癌症疫苗市场驱动因素
    • 市场驱动因素的影响分析
  • 新抗原癌症疫苗市场限制
    • 市场限制影响分析
  • 新抗原癌症疫苗市场机会
  • 新抗原癌症疫苗市场未来趋势

第 4 章:新抗原癌症疫苗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章:新抗原癌症疫苗市场:COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章:新抗原癌症疫苗市场格局

  • 2023 年新抗原癌症疫苗市场份额分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章:新抗原癌症疫苗市场 - 副产品

  • 概述
    • 按产品分類的细分市场占有率分析
    • 个人化
    • 现成的

第 8 章:新抗原癌症疫苗市场 - 按类型

  • 概述
    • 按类型分類的细分市场占有率分析
    • 树突状细胞
    • 核酸
    • 合成长胜肽
    • 肿瘤细胞

第 9 章:新抗原癌症疫苗市场 - 按给药途径

  • 概述
    • 按给药途径分類的细分市场份额分析
    • 肌肉注射
    • 静脉
    • 透皮

第 10 章:新抗原癌症疫苗市场 - 按传递机制

  • 概述
    • 按交付机制分類的细分市场占有率分析
    • 脂质体
    • 病毒体
    • 基因枪
    • 电穿孔
    • 其他的

第 11 章:新抗原癌症疫苗市场 - 按应用

  • 概述
    • 按应用分類的细分市场占有率分析
    • 脑癌
    • 胃肠癌
    • 肺癌
    • 黑色素瘤
    • 其他的

第 12 章:新抗原癌症疫苗市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美新抗原癌症疫苗主要製造商
    • 北美市场规模和预测(按国家)
    • 北美市场规模和预测(按产品)
    • 北美市场规模和预测(按类型)
    • 北美市场规模与预测(按管理途径)
    • 北美市场规模和预测(按交付机制)
    • 北美市场规模和预测(按应用)
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲新抗原癌症疫苗主要製造商
    • 欧洲市场规模和预测(按国家)
    • 欧洲市场规模和预测(按产品)
    • 欧洲市场规模与预测(按类型)
    • 欧洲市场规模与预测(按管理途径)
    • 欧洲市场规模和预测(按交付机制)
    • 欧洲市场规模和预测(按应用)
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区新抗原癌症疫苗主要製造商
    • 亚太地区市场规模与预测(按国家)
    • 亚太地区市场规模与预测(按产品)
    • 亚太地区市场规模与预测(按类型)
    • 亚太地区市场规模与预测(依管理途径)
    • 亚太地区市场规模与预测(按交付机制)
    • 亚太地区市场规模与预测(按应用)
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲新抗原癌症疫苗主要製造商
    • 拉丁美洲市场规模与预测(按国家)
    • 拉丁美洲市场规模与预测(按产品)
    • 拉丁美洲市场规模与预测(按类型)
    • 拉丁美洲市场规模与预测(按管理途径)
    • 拉丁美洲市场规模与预测(按交付机制)
    • 拉丁美洲市场规模与预测(按应用)
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲新抗原癌症疫苗主要製造商
    • 中东和非洲市场规模及预测(按国家)
    • 中东和非洲市场规模及预测(按产品)
    • 中东和非洲市场规模及预测(按类型)
    • 中东和非洲市场规模及预测(按管理途径)
    • 中东和非洲市场规模及预测(按交付机制)
    • 中东和非洲市场规模及预测(按应用)
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 13 章:主要供应商分析-新抗原癌症疫苗产业

  • 竞争仪表板
  • 公司简介
    • OSE Immunotherapeutics SA
    • Gritstone bio Inc.
    • BioNTech SE
    • Hoffmann-La Roche Ltd.
    • Pfizer Inc.
    • Merck & Co. Inc.
    • Moderna Inc.
    • Avidea Technologies Inc.
    • Eli Lilly and Company
    • Vaccibody AS
    • Agenus Inc.
    • Novogene Co. Ltd.
    • ZIOPHARM Oncology Inc.
    • ISA Pharmaceuticals BV
    • BrightPath Biotherapeutics Co. Ltd.
    • Vaximm AG
    • Medigene AG
    • Genocea Biosciences Inc.
    • Advaxis Inc.
    • Nouscom AG
    • Others

第 14 章:360 度分析师视角

第 15 章:附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4229

REPORT HIGHLIGHT

The Neoantigen Cancer Vaccine Market size was valued at USD 46,059.43 million in 2023, expanding at a CAGR of 73.40% from 2024 to 2032.

Neoantigen cancer vaccines constitute a form of personalized immunotherapy aimed at activating the immune system to identify and combat cancerous cells. These vaccines focus on neoantigens, which are unique antigens generated from mutations within tumor cells. The development of neoantigen cancer vaccines marks a notable progression in the field of cancer immunotherapy, utilizing the distinct features of an individual's tumor to bolster the body's inherent capacity to combat cancer.

Neoantigen Cancer Vaccine Market- Market Dynamics

The growing adoption of personalized medicine aimed at customizing patient treatment is anticipated to propel market expansion. This approach emphasizes the development of treatment plans that are specifically designed to align with individual patient characteristics, such as genetic profiles, tumor features, and overall health status. Central to this methodology are Neoantigen vaccines, which are meticulously crafted based on the distinct mutations found in a patient's tumor. Notably, the number of personalized medicines available in the market increased from 132 to 286, with these therapies representing 25% of the new drugs approved by the FDA in 2019.

Moreover, enhanced funding from both public and private sectors, including contributions from pharmaceutical companies and venture capitalists, is driving research and development efforts in this domain. Nevertheless, the complexity of manufacturing processes may pose challenges to market growth.

Neoantigen Cancer Vaccine Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 73.40% over the forecast period (2024-2032)

Based on Product segmentation, Personalized was predicted to show maximum market share in the year 2023

Based on Type segmentation, Nucleic Acid was the leading type in 2023

Based on Application segmentation, Lung Cancer was the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Neoantigen Cancer Vaccine Market- Segmentation Analysis:

The Global Neoantigen Cancer Vaccine Market is segmented based on Product, Type, Route of Administration, Delivery Mechanism, Application, and Region.

The market is classified into two segments according to product: Personalized and Off-the-shelf. The Personalized segment holds a dominant position in the market. Personalized neoantigen vaccines are frequently used in conjunction with checkpoint inhibitors, such as PD-1 or CTLA-4 inhibitors, to enhance the immune response. This combinatorial strategy is under investigation to address the shortcomings of existing immunotherapies and to enhance patient outcomes.

The market is segmented into four categories according to type: Dendritic Cell, Nucleic Acid, Synthetic Long Peptide, and Tumor Cell. The Nucleic Acid category holds a leading position in the market. The Neoantigen Cancer Vaccine Market is significantly linked to progress in nucleic acid technologies, especially in the creation of novel vaccines aimed at addressing tumor-specific mutations.

The market is segmented into three categories according to the Route of Administration: Intramuscular, Intravenous, and Transdermal. The Neoantigen Cancer Vaccine Market is experiencing significant growth, with different routes of administration being essential for the advancement and distribution of these tailored therapies.

The market is categorized into four segments according to the Delivery Mechanism: Liposomes, Virosomes, Gene gun, Electroporation, and Others. These mechanisms are essential for effectively delivering personalized vaccines to the targeted cells, thereby facilitating a robust immune response to the cancer-specific neoantigens.

The market is segmented into four categories according to application: Brain Cancer, Gastrointestinal Cancer, Lung Cancer, Melanoma, and Others. Lung Cancer holds a leading position in the market. In the case of lung cancer, the elevated mutation burden offers a diverse range of potential neoantigens for targeting, thereby positioning personalized vaccines as a highly promising approach.

Neoantigen Cancer Vaccine Market- Geographical Insights

North America features a robust clinical trial framework, with a multitude of research institutions and hospitals engaged in the development of Neoantigen vaccines. The regulatory landscape in this region facilitates streamlined trial processes, promoting the advancement and evaluation of innovative therapies. Cancer has impacted nearly every individual in the United States, and there is significant public support for increased funding in cancer research. A recent survey conducted by ASCO, involving over 4,000 Americans, revealed that approximately 73% believe the government should allocate more resources to discovering treatments and cures for cancer, even if this necessitates higher taxes or an increase in the national deficit. Europe represents the second largest region for market expansion, driven by advancements in genomic technologies. Overall, the global environment for Neoantigen cancer vaccines is vibrant, presenting numerous growth opportunities across different regions.

Neoantigen Cancer Vaccine Market- Competitive Landscape:

The Neoantigen cancer vaccine market exhibits a highly competitive environment, with major players actively utilizing cutting-edge technologies, establishing strategic alliances, and making significant investments in research and development. These companies are collaborating with research institutions, healthcare facilities, and other biotechnology firms to strengthen their R&D efforts and accelerate the creation of neoantigen vaccines. The competitive landscape is expected to change swiftly, driven by continuous technological advancements and a commitment to enhancing patient outcomes.

Recent Developments:

On September 10, 2024, OSE Immunotherapeutics SA announced the commencement of its international Phase 3 clinical trial, named 'Artemia,' for Tedopi, a therapeutic cancer vaccine based on neoepitopes intended for off-the-shelf application. This trial is aimed at providing second-line treatment for patients diagnosed with metastatic non-small cell lung cancer (NSCLC). The study has received review and approval from health authorities across 14 countries, including the US FDA, Canada, Europe, and the United Kingdom, marking a significant advancement in the registration process for Tedopi, in conjunction with the development of a companion diagnostic for HLA-A2 positive patients.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NEOANTIGEN CANCER VACCINE MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • OSE Immunotherapeutics SA
  • Gritstone Bio Inc.
  • BioNTech SE
  • Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Merck & Co. Inc.
  • Moderna Inc.
  • Avidea Technologies Inc.
  • Eli Lilly and Company
  • Vaccibody AS
  • Agenus Inc.
  • Novogene Co. Ltd.
  • ZIOPHARM Oncology Inc.
  • ISA Pharmaceuticals B.V.
  • BrightPath Biotherapeutics Co. Ltd.
  • Vaximm AG
  • Medigene AG
  • Genocea Biosciences Inc.
  • Advaxis Inc.
  • Nouscom AG
  • Others

GLOBAL NEOANTIGEN CANCER VACCINE MARKET, BY PRODUCT- MARKET ANALYSIS, 2019 - 2032

  • Personalized
  • Off-the-shelf

GLOBAL NEOANTIGEN CANCER VACCINE MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Dendritic Cell
  • Nucleic Acid
  • Synthetic Long Peptide
  • Tumor Cell

GLOBAL NEOANTIGEN CANCER VACCINE MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Intramuscular
  • Intravenous
  • Transdermal

GLOBAL NEOANTIGEN CANCER VACCINE MARKET, BY DELIVERY MECHANISM- MARKET ANALYSIS, 2019 - 2032

  • Liposomes
  • Virosomes
  • Gene gun
  • Electroporation
  • Others

GLOBAL NEOANTIGEN CANCER VACCINE MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Brain Cancer
  • Gastrointestinal Cancer
  • Lung Cancer
  • Melanoma
  • Others

GLOBAL NEOANTIGEN CANCER VACCINE MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Neoantigen Cancer Vaccine Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Neoantigen Cancer Vaccine Market Snippet by Product
    • 2.1.2. Neoantigen Cancer Vaccine Market Snippet by Type
    • 2.1.3. Neoantigen Cancer Vaccine Market Snippet by Route of Administration
    • 2.1.4. Neoantigen Cancer Vaccine Market Snippet by Delivery Mechanism
    • 2.1.5. Neoantigen Cancer Vaccine Market Snippet by Application
    • 2.1.6. Neoantigen Cancer Vaccine Market Snippet by Country
    • 2.1.7. Neoantigen Cancer Vaccine Market Snippet by Region
  • 2.2. Competitive Insights

3. Neoantigen Cancer Vaccine Key Market Trends

  • 3.1. Neoantigen Cancer Vaccine Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Neoantigen Cancer Vaccine Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Neoantigen Cancer Vaccine Market Opportunities
  • 3.4. Neoantigen Cancer Vaccine Market Future Trends

4. Neoantigen Cancer Vaccine Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Neoantigen Cancer Vaccine Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Neoantigen Cancer Vaccine Market Landscape

  • 6.1. Neoantigen Cancer Vaccine Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Neoantigen Cancer Vaccine Market - By Product

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product, 2023 & 2032 (%)
    • 7.1.2. Personalized
    • 7.1.3. Off-the-shelf

8. Neoantigen Cancer Vaccine Market - By Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 8.1.2. Dendritic Cell
    • 8.1.3. Nucleic Acid
    • 8.1.4. Synthetic Long Peptide
    • 8.1.5. Tumor Cell

9. Neoantigen Cancer Vaccine Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 9.1.2. Intramuscular
    • 9.1.3. Intravenous
    • 9.1.4. Transdermal

10. Neoantigen Cancer Vaccine Market - By Delivery Mechanism

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Delivery Mechanism, 2023 & 2032 (%)
    • 10.1.2. Liposomes
    • 10.1.3. Virosomes
    • 10.1.4. Gene gun
    • 10.1.5. Electroporation
    • 10.1.6. Others

11. Neoantigen Cancer Vaccine Market - By Application

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Application, 2023 & 2032 (%)
    • 11.1.2. Brain Cancer
    • 11.1.3. Gastrointestinal Cancer
    • 11.1.4. Lung Cancer
    • 11.1.5. Melanoma
    • 11.1.6. Others

12. Neoantigen Cancer Vaccine Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Neoantigen Cancer Vaccine Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Neoantigen Cancer Vaccine Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.10. Italy
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. Italy Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.3.10.4. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.10.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.10.6. Italy Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.3.10.7. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.11. United Kingdom
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. United Kingdom Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.3.11.4. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.11.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.11.6. United Kingdom Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.3.11.7. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.12. France
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. France Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.3.12.4. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.12.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.12.6. France Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.3.12.7. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.13. Russia
      • 12.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.2. Russia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.3.13.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Russia Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.14. Netherlands
      • 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.2. Netherlands Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.3.14.3. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.14.5. Netherlands Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.3.14.6. Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.2. Sweden Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.16. Poland
      • 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.2. Poland Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.3.16.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Poland Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.17. Rest of Europe
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Rest of the Europe Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Rest of the Europe Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Neoantigen Cancer Vaccine Key Manufacturers in Asia Pacific
    • 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. Asia Pacific Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 12.4.5. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.4.7. Asia Pacific Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
    • 12.4.8. Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.9. India
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. India Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.4.9.4. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.9.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.9.6. India Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.4.9.7. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.10. China
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. China Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.4.10.4. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.10.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.10.6. China Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.4.10.7. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.14. Thailand
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Thailand Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Thailand Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.15. Indonesia
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Indonesia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Indonesia Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.5. Latin America
    • 12.5.1. Overview
    • 12.5.2. Neoantigen Cancer Vaccine Key Manufacturers in Latin America
    • 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. Latin America Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 12.5.5. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.5.7. Latin America Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
    • 12.5.8. Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Neoantigen Cancer Vaccine Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Neoantigen Cancer Vaccine Industry

  • 13.1. Competitive Dashboard
  • 13.2. Company Profiles
    • 13.2.1. OSE Immunotherapeutics SA
    • 13.2.2. Gritstone bio Inc.
    • 13.2.3. BioNTech SE
    • 13.2.4. Hoffmann-La Roche Ltd.
    • 13.2.5. Pfizer Inc.
    • 13.2.6. Merck & Co. Inc.
    • 13.2.7. Moderna Inc.
    • 13.2.8. Avidea Technologies Inc.
    • 13.2.9. Eli Lilly and Company
    • 13.2.10. Vaccibody AS
    • 13.2.11. Agenus Inc.
    • 13.2.12. Novogene Co. Ltd.
    • 13.2.13. ZIOPHARM Oncology Inc.
    • 13.2.14. ISA Pharmaceuticals B.V.
    • 13.2.15. BrightPath Biotherapeutics Co. Ltd.
    • 13.2.16. Vaximm AG
    • 13.2.17. Medigene AG
    • 13.2.18. Genocea Biosciences Inc.
    • 13.2.19. Advaxis Inc.
    • 13.2.20. Nouscom AG
    • 13.2.21. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us